GLSI
NASDAQ · Biotechnology
Greenwich Lifesciences Inc
$23.86
+0.24 (+1.02%)
Open$23.13
Previous Close$23.62
Day High$24.01
Day Low$22.91
52W High$34.10
52W Low$7.78
Volume—
Avg Volume105.6K
Market Cap327.24M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+42.7% upside
Current
$23.86
$23.86
Target
$34.05
$34.05
$25.54
$34.05 avg
$45.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 64.12M | 62.89M | 59.76M |
| Net Income | 10.06M | 8.97M | 9.50M |
| Profit Margin | 15.7% | 14.3% | 15.9% |
| EBITDA | 19.32M | 16.62M | 17.12M |
| Free Cash Flow | 7.72M | 11.60M | 9.03M |
| Rev Growth | -9.0% | -7.6% | +0.6% |
| Debt/Equity | 0.70 | 0.55 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |